|
Baseline characteristics of coagulopathic and non-coagulopathic patients |
|||
| Coagulopathic patients (n = 136) |
Non-coagulopathic patients (n = 104) |
P value |
|
|
|
|||
| RBCs prior to trial drug, units (n) |
8.4 ± 1.6 (134) |
8.4 ± 1.4 (98) |
1.00 |
| FFP prior to trial drug, ml (n) |
922 ± 627 (102) |
95 ± 178 (88) |
<0.001 |
| Platelets prior to trial drug, ml (n) |
126 ± 181 (128) |
0 ± 0 (100) |
<0.001 |
| Cryoprecipitate prior to trial drug, ml (n) |
28 ± 78 (135) |
0 ± 0 (104) |
<0.001 |
|
|
|||
| FFP after trial drug to 48 hours, ml (n) |
1,596 ± 1,777 (102) |
1,499 ± 1,927 (88) |
0.72 |
| Platelets after trial drug to 48 hours, ml (n) |
289 ± 341 (127) |
319 ± 432 (100) |
0.57 |
| Cryoprecipitate after trial drug to 48 hours, ml (n) |
56 ± 151 (135) |
33 ± 121 (104) |
0.19 |
|
|
|||
| Injury severity score (n) |
30 ± 13 (131) |
26 ± 13 (104) |
0.02 |
| Temperature, °C (n) |
35.1 ± 1.4 (92) |
35.2 ± 1.5 (62) |
0.68 |
| Mean arterial pressure, mm Hg (n) |
76 ± 22 (132) |
74 ± 18 (101) |
0.45 |
| pH (n) |
7.28 ± 0.11 (130) |
7.24 ± 0.12 (101) |
0.01 |
| Hematocrit, percentage (n) |
25 ± 8 (104) |
28 ± 9 (83) |
0.02 |
| aPTT, seconds (n) |
50 ± 25 (79) |
54 ± 30 (51) |
0.43 |
| PT, seconds (n) |
19 ± 6 (90) |
21 ± 6 (58) |
0.05 |
| Platelet count, × 109 (n) |
78 ± 45 (122) |
70 ± 47 (98) |
0.20 |
| Fibrinogen, g/l (n) |
1.3 ± 0.7 (90) |
1.2 ± 1.2 (58) |
0.57 |
| 48-hour mortality, n (percentage) |
21 (15) |
20 (19) |
0.44 |
|
|
|||
| 30-day mortality, n (percentage) |
32 (24) |
29 (28) |
0.44 |
|
Data are mean ± standard deviation or number (percentage). aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; PT, prothrombin time; RBC, red blood cell. | |||
Rizoli et al. Critical Care 2006 10:R178 doi:10.1186/cc5133 |
|||